Invitae

Ciitizen Corporation is a healthcare technology company based in Palo Alto, California, that operates a digital platform designed to empower patients to collect, organize, and share their personal health information, including genomic data and lab results. Founded in 2017, Ciitizen aims to give individuals control over their complete health records, facilitating the sharing of this information with caregivers, researchers, and other relevant parties. The platform addresses the limitations of existing health data portals, which often provide only minimal information and rely on labor-intensive processes to extract insights from unstructured data. By normalizing diverse health information into actionable formats, Ciitizen enhances transparency and accessibility for patients and healthcare providers alike. The company is led by CEO Anil Sethi and is supported by a prominent investment team.

Genosity is a life science biotechnology company focused on providing tools and services for clinical research applications of genomics. They provide novel software solutions and laboratory services for both somatic and germline applications to enable their strategic partners to fully realize the value of precision medicine for both the research and clinical markets.

One Codex is a data platform focused on applied microbial genomics, offering bioinformatics solutions that facilitate applications in clinical diagnostics, food safety, and biosecurity. The company specializes in developing scalable and secure platforms for metagenomics and microbial genomics, emphasizing usability to cater to applied microbiologists. By providing access to a comprehensive microbial reference database, One Codex enables rapid and straightforward microbiome analysis, enhancing the capabilities of professionals in the field.

ArcherDX, Inc. is a genomics company headquartered in Boulder, Colorado, specializing in the development and commercialization of advanced genetic analysis products. Established in 2013, the company focuses on next-generation sequencing technologies to enhance genetic mutation detection, particularly in oncology. ArcherDX offers a range of research-use-only products, including DNA-based VariantPlex, RNA-based FusionPlex, and ctDNA-based LiquidPlex assays. These products enable laboratories to conduct genomic analyses for therapy optimization and cancer monitoring. Additionally, ArcherDX provides customized assay design services for clinical and biopharmaceutical clients, allowing them to target specific biomarkers and develop new applications. The company aims to deliver actionable genomic information for the treatment of solid tumors, blood cancers, and sarcomas, catering to academic laboratories, biopharmaceutical firms, and contract research organizations. ArcherDX also seeks regulatory approval for various companion diagnostic assays to further support precision medicine initiatives.

Genelex Corporation, based in Seattle, Washington, operates as a DNA testing laboratory specializing in pharmacogenetic testing. Founded in 1987, the company provides a personalized medication management program that includes DNA sensitivity testing and the GeneMedRx software, which assesses potential drug-drug and drug-gene interaction risks based on genetic profiles. Genelex also offers a range of services, including parentage and forensic DNA testing, ancestry DNA testing, and clinical trial genotyping. Additionally, the company markets various at-home and legally admissible DNA tests, such as grandpaternity, maternity, and paternity tests, alongside predictive genetic assessments. Genelex is dedicated to reducing the risk of adverse drug events through its innovative testing and analytical capabilities. As of April 2020, Genelex operates as a subsidiary of Invitae Corporation.

Diploid is a biotechnology services provider that specializes in clinical genome interpretation. The company has developed software that utilizes artificial intelligence to analyze human genome data, transforming raw genetic information into comprehensive reports. These reports identify novel variants responsible for genetic disorders and rare diseases. By outsourcing clinical genome interpretation to Diploid, hospitals and clinical laboratories can alleviate their workload and enhance diagnostic accuracy, ultimately improving patient care.

Clear Genetics, Inc. is a digital health company that specializes in providing genetic counseling services to women, healthcare providers, and health systems. Founded in 2016 and based in San Francisco, California, the company offers a web application called Clearancy, which delivers personalized genetic information for patients undergoing genetic testing and their medical practitioners. Clear Genetics focuses on various medical specialties, including prenatal care, cardiology, carrier screening, hereditary cancer, and pediatrics. By partnering with health systems, laboratories, and academic institutions, Clear Genetics aims to enhance patient access to genetic counseling and testing, facilitating the thoughtful integration of genetics into routine patient care. As of November 2019, Clear Genetics operates as a subsidiary of Invitae Corporation.

Jungla Inc., headquartered in South San Francisco, is a biotechnology company focused on enhancing disease diagnosis and drug development through its molecular function software platform. Established in 2016, the company integrates advancements in functional genomics, computational biophysics, and computer science to provide healthcare and drug companies with quantitative, model-driven insights into genomic variants. This innovative approach aims to improve the accuracy of clinical genetic testing, addressing shortcomings in existing market solutions. By delivering robust and scalable results, Jungla empowers healthcare providers to expedite diagnostic development and treatment processes. As a subsidiary of Invitae Corporation, Jungla is supported by prominent technology and healthcare investors, reflecting its commitment to advancing precision medicine.

Singular Bio, Inc. is a San Francisco-based company founded in 2012 that specializes in diagnostic testing for personalized medicine. The company has developed a cutting-edge technology for single molecule analysis of DNA, which offers exceptional sensitivity in detecting various common health conditions. Singular Bio's proprietary detection system aims to address the needs of high-volume healthcare testing, combining the accuracy of genetic analysis with the affordability and rapid results typically associated with screening tests. By leveraging advanced optics alongside custom molecular biology and chemistry, Singular Bio seeks to enhance healthcare accessibility and enable early detection of medical conditions for a broader population. As of mid-2019, Singular Bio operates as a subsidiary of Invitae Corporation.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, focused on genetic screening for inherited diseases. Founded in 2007, the company aims to transform reproductive medicine by providing physicians and patients with actionable insights into inherited genetic disorders. Good Start Genetics offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. The company employs advanced next-generation DNA sequencing technology, along with other established genetic screening methods, to deliver high carrier detection rates. Additionally, through its GoodStart Select program, it provides a comprehensive menu of genetic carrier screening tests for both known and novel mutations, all supported by a commitment to customer care and genetic counseling. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

CombiMatrix Corporation, now a subsidiary of Invitae Corporation since 2017, specializes in clinical molecular diagnostic laboratory services in the United States. The company primarily focuses on pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. CombiMatrix employs advanced technologies such as single nucleotide polymorphism analysis, chromosomal microarray analysis, next-generation sequencing, fluorescent in situ hybridization, and high-resolution karyotyping to detect genetic abnormalities that traditional methods may miss. Its services are utilized by physicians, hospitals, and clinics, catering to commercial insurance companies, government payors, and individual patients. Founded in 1995 and originally based in Mukilteo, Washington, CombiMatrix has developed proprietary technologies and products for genetic analysis and diagnostics, enhancing patient care through innovative molecular diagnostics.

CancerGene Connect is a developer of a cloud-based genetic assessment platform that focuses on collecting, assessing, and managing genetic family histories. The platform enhances genetic counseling programs by streamlining the collection of family medical histories and facilitating cancer risk assessments. This innovative approach allows clinicians to dedicate more time to addressing patient risks, as it significantly reduces the time spent on organizing data. By leveraging evolving technology, CancerGene Connect aims to create powerful connections between patients and healthcare providers, ultimately improving the overall effectiveness of cancer risk management.

AltaVoice is a patient-centered data company based in Silicon Valley that focuses on optimizing the search for better treatments for various diseases. The company builds and hosts Patient Insights Networks (PINs), which are designed to efficiently collect, curate, and share health data reported by patients and clinicians. By collaborating with drug developers, advocacy organizations, and academic researchers, AltaVoice facilitates the unification of data collection efforts while ensuring that advocacy organizations maintain their brand presence. Their PINs enable faster delivery of patient insights compared to traditional registries and contract research organizations. Since its establishment in 2007, AltaVoice has developed programs for over 400 diseases, working with more than 100 advocacy groups, as well as institutions like the NIH and PCORI. The company gained recognition for its innovative contributions to the field, including an invitation to participate in the Cancer Moonshot events at the White House in 2016.